Immunosyn reports completion of first phase diabetic ulcer trial

The primary purpose of the ‘proof of concept trial’ is to further evaluate the safety and efficacy of SF-1019 in the treatment of diabetic ulceration and its effect on diabetic polyneuropathy in type 1 diabetes mellitus by both subcutaneous injection and by topical application. The Board of Immunosyn was advised as to the success of this important phase of the ‘proof of concept trial’ by Argyll Biotechnologies, its strategic partner and largest shareholder.

It is expected that the next phase will be completed during the first half of 2008 and that larger-scale independently-managed formal clinical trials, leading to a licensed product in Europe, will take place shortly thereafter at a specialist wound healing clinic.

Angus Dalgleish, chief scientist of Argyll Biotechnologies, said: “This first very important phase in the development of SF-1019, which was undertaken at a European venue, has indicated that SF-1019 promotes wound healing and almost certainly induces growth factors.”